Otsuka Holdings Co Ltd (OTSKY)
20.59
-0.22
(-1.06%)
USD |
OTCM |
May 21, 15:58
Otsuka Holdings Enterprise Value: 20.52B for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 20.52B |
| May 17, 2024 | 20.60B |
| May 16, 2024 | 20.83B |
| May 15, 2024 | 21.00B |
| May 14, 2024 | 20.99B |
| May 13, 2024 | 20.87B |
| May 10, 2024 | 20.74B |
| May 09, 2024 | 20.56B |
| May 08, 2024 | 20.26B |
| May 07, 2024 | 20.46B |
| May 06, 2024 | 20.50B |
| May 03, 2024 | 20.33B |
| May 02, 2024 | 20.14B |
| May 01, 2024 | 20.34B |
| April 30, 2024 | 21.00B |
| April 29, 2024 | 20.35B |
| April 26, 2024 | 20.15B |
| April 25, 2024 | 19.68B |
| April 24, 2024 | 20.06B |
| April 23, 2024 | 20.26B |
| April 22, 2024 | 20.13B |
| April 19, 2024 | 19.86B |
| April 18, 2024 | 19.60B |
| April 17, 2024 | 19.85B |
| April 16, 2024 | 20.15B |
| Date | Value |
|---|---|
| April 15, 2024 | 20.06B |
| April 12, 2024 | 20.19B |
| April 11, 2024 | 20.24B |
| April 10, 2024 | 20.23B |
| April 09, 2024 | 20.19B |
| April 08, 2024 | 20.37B |
| April 05, 2024 | 20.23B |
| April 04, 2024 | 20.30B |
| April 03, 2024 | 20.77B |
| April 02, 2024 | 20.62B |
| April 01, 2024 | 20.67B |
| March 31, 2024 | 20.44B |
| March 28, 2024 | 20.03B |
| March 27, 2024 | 20.39B |
| March 26, 2024 | 20.05B |
| March 25, 2024 | 20.12B |
| March 22, 2024 | 20.61B |
| March 21, 2024 | 20.49B |
| March 20, 2024 | 20.36B |
| March 19, 2024 | 20.26B |
| March 18, 2024 | 20.44B |
| March 15, 2024 | 19.59B |
| March 14, 2024 | 19.38B |
| March 13, 2024 | 19.48B |
| March 12, 2024 | 19.54B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
13.15B
Minimum
Mar 06 2023
23.68B
Maximum
Feb 06 2020
18.58B
Average
18.59B
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 70.56B |
| Nxera Pharma Co Ltd | 1.009B |
| PeptiDream Inc | 1.517B |
| Healios KK | 62.31M |
| AnGes Inc | 59.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 521.35M |
| Revenue (Quarterly) | 3.500B |
| Total Expenses (Quarterly) | 2.929B |
| EPS Diluted (Quarterly) | 0.4804 |
| Gross Profit Margin (Quarterly) | 70.78% |
| Profit Margin (Quarterly) | 14.89% |
| Earnings Yield | 4.29% |
| Operating Earnings Yield | 9.48% |
| Normalized Earnings Yield | 8.352 |